LNTHLantheus Holdings, Inc.
$100.15+99% 1Y
$100.15
$50.1152 weeks$109.01
The financials
Lantheus Holdings, Inc. by the numbers
Lantheus Holdings, Inc. (LNTH) reported revenue of $388M in Q2 2026 (quarter ended Jun 30, 2026), up 2.7% from the same quarter a year earlier. That came with a gross margin of 62% and net income of $75M (19% of revenue). For the full year FY2025, revenue was $1.54B (+0.5% year on year) and net income $234M. Its largest product in Q2 2026 was PYLARIFY at $240M, 55% of the disclosed total, well ahead of Cardiology at 20%. The next results filing is expected around Nov 5, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $388M | $378M | +2.7% |
| Gross profit | $242M | $241M | +0.4% |
| Operating income | $100M | $88M | +14% |
| Net income | $75M | $79M | −4.7% |
| Diluted EPS | $1.11 | $1.12 | −0.9% |
| Product | Revenue | Share |
|---|---|---|
| PYLARIFY | $240M | 55% |
| Cardiology | $88M | 20% |
| Neuraceq | $40M | 9.0% |
| Neurology | $40M | 9.0% |
| Strategic Partnerships And Other | $20M | 4.5% |
| Licenseand Royalty | $11M | 2.6% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $439.0M (+4.5%)
License and Royalty grew +222% year on yearSPECT Business -100% year on year
Segment Latestquarter on quarteryear on year
- PYLARIFY$240.4M$240.4Mquarter on quarter -0.23%year on year -4.1%-0.23%-4.1%
- Cardiology$88.3M$88.3Mquarter on quarter +4.3%year on year +5.2%+4.3%+5.2%
- Neuraceq$39.6M$39.6Mquarter on quarter +12%year on year n/a+12%n/a
- Neurology$39.6M$39.6Mquarter on quarter +12%year on year n/a+12%n/a
- Strategic Partnerships And Other$19.9M$19.9Mquarter on quarter +22%year on year +72%+22%+72%
- License and Royalty$11.2M$11.2Mquarter on quarter +50%year on year +222%+50%+222%
- SPECT Business$0.00$0.00quarter on quarter n/ayear on year -100%n/a-100%
Drug Manufacturers, Specialty & Generic
Ranks #5 of 41 by RyuScore